Monocyte Activation Test Market Report 2026

The monocyte activation test market size has grown rapidly in recent years. It will grow from $0.54 billion in 2025 to $0.63 billion in 2026 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to increasing biologics development activities, rising regulatory scrutiny on pyrogen safety, replacement of animal-based testing methods, expansion of pharmaceutical quality control testing, growing investment in in vitro testing technologies.

The monocyte activation test market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing adoption of advanced biologics and vaccines, rising demand for high-throughput safety testing, expansion of automated laboratory workflows, growing regulatory support for animal-free testing, increasing integration of digital lab platforms. Major trends in the forecast period include increasing adoption of animal-free pyrogen testing, rising use of automated mat assay systems, growing integration of data management software, expansion of gmp-compliant testing solutions, enhanced focus on regulatory acceptance of mat.

The rising prevalence of autoimmune disorders is expected to drive the growth of the monocyte activation test (MAT) market in the coming years. Autoimmune disorders are conditions in which the body’s immune system mistakenly attacks its own healthy cells, tissues, or organs rather than defending against infections and foreign substances. The increasing prevalence of autoimmune disorders is primarily attributed to greater exposure to environmental pollutants, which can disrupt immune regulation and trigger abnormal responses. The monocyte activation test aids in detecting autoimmune disorders by providing a reliable method for assessing immune system activation. It helps identify abnormal immune responses, which is crucial for diagnosing conditions such as lupus and rheumatoid arthritis, thereby improving early detection and management of these diseases. For instance, in February 2024, according to Arthritis Australia, a non-profit organization based in Australia, an estimated 562,378 Australians will be living with rheumatoid arthritis (RA) in 2025, representing 14% of all arthritis cases that year. By 2040, this number is projected to increase by 33% to 748,721, representing an additional 186,343 Australians with RA compared with 2025. Therefore, the rising incidence of autoimmune disorders is driving the growth of the monocyte activation test market.

The increasing occurrence of healthcare-associated infections (HAIs) is also expected to propel the growth of the monocyte activation test market. Healthcare-associated infections are infections acquired by patients while receiving care in a medical facility. The rise in HAIs is driven by the increased use of invasive medical devices, which can introduce pathogens into the body and elevate infection risk. The monocyte activation test helps address healthcare-associated infections by detecting pyrogens early, ensuring safer medical devices and injectable products, and reducing the risk of infection-related complications. For instance, in January 2025, the National Library of Medicine, a US-based organization providing extensive biomedical literature and data, reported that among 13,654 patients in 218 hospitals, 357 patients (2.6%) experienced 392 HAIs. Patients with HAIs were more frequently found in large hospitals and critical care units compared with patients without HAIs. Therefore, the increasing prevalence of healthcare-associated infections is driving the growth of the monocyte activation test market.

Key companies operating in the monocyte activation test market are focusing on developing advanced MAT products, such as pyrogen and endotoxin tests, to enhance sensitivity and improve the detection of immune responses. Pyrogen and endotoxin tests are used to identify substances that induce fever, particularly endotoxins from gram-negative bacteria. For instance, in June 2024, FUJIFILM Wako Pure Chemicals Corporation, a Japan-based chemical manufacturer, launched the LumiMAT Pyrogen Detection Kit, a next-generation monocyte activation test for in vitro pyrogen screening, along with PYROSTAR Neo+, a recombinant protein reagent for detecting bacterial endotoxins. These products improve the accuracy, efficiency, and safety of pyrogen testing in pharmaceutical and biotechnology applications.

Major companies operating in the monocyte activation test market are Merck KGaA, Becton Dickinson and Company, Eurofins Scientific, Lonza Group, Charles River Laboratories, Nelson Laboratories LLC, Solvias AG, Labor LS SE and Co. KG, BMG Labtech, Cellular Technology Limited, Creative Biolabs, FUJIFILM Wako Chemicals, Microcoat Biotechnologie GmbH, MAT BioTech B.V., Sanquin Diagnostiek B.V., PyroDex LLC, MAT Research B.V., Minerva Biolabs GmbH, Wickham Micro Limited, Rapid Test Methods Ltd.

North America was the largest region in the monocyte activation test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monocyte activation test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the monocyte activation test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the monocyte activation test market by increasing costs of imported reagents, assay kits, analytical instruments, and laboratory automation components used in pharmaceutical and medical device testing. Europe and North America are most affected due to dependence on specialized imported reagents and assay platforms, while Asia-Pacific faces higher costs for scaling laboratory infrastructure. These tariffs are raising operational costs for testing laboratories and manufacturers. However, they are also encouraging local reagent production, regional assay development, and increased investment in domestic laboratory manufacturing capabilities.

The monocyte activation test market research report is one of a series of new reports that provides monocyte activation test market statistics, including monocyte activation test industry global market size, regional shares, competitors with a monocyte activation test market share, detailed monocyte activation test market segments, market trends and opportunities, and any further data you may need to thrive in the monocyte activation test industry. This monocyte activation test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The monocyte activation test (MAT) is an in vitro method used to detect pyrogens by measuring cytokine release, particularly interleukin-6 (IL-6), from human monocytes. It closely mimics the human immune response compared to traditional animal tests. The primary purpose of MAT is to ensure pyrogen safety in pharmaceuticals, especially biologics and medical devices.

The primary product types of the monocyte activation test include reagents, test kits, assay systems, and software solutions. Reagents are specialized chemical or biological substances used to stimulate or detect immune responses, enabling accurate identification of pyrogenic contaminants. MAT employs technologies such as enzyme-linked immunosorbent assay (ELISA), flow cytometry, polymerase chain reaction (PCR), and Luminex. Products are distributed through channels including direct sales, distributors or third-party partners, online retailers, and institutional sales. MAT is applied in areas such as drug development, vaccine development, medical device testing, and others, and is used by end users including pharmaceutical companies, biotechnology companies, research institutions, hospitals, and laboratories.

The monocyte activation test market consists of revenues earned by entities by providing services such as pyrogen detection testing, batch release testing, medical device testing, vaccine and biologic testing, and customized test development. The market value includes the value of related goods sold by the service provider or included within the service offering. The monocyte activation test market also includes sales of cryopreserved human monocytes, cytokine detection kits, culture media and buffers, and pyrogen-free consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.